Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 11 - 17 |
| Updated: | 6/30/2018 |
| Start Date: | October 2004 |
| End Date: | March 2006 |
A Phase 2, Randomized, Single-blind, Controlled, Multicenter Study to Compare the Safety and Immune Response of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With the Safety and Immune Response of One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Adolescents 11 to 17 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of Novartis
Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide
vaccine administered to healthy adolescents ages 11 to 17 years.
Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide
vaccine administered to healthy adolescents ages 11 to 17 years.
Inclusion Criteria:
- Healthy adolescents between and including 11-17 years of age, who provide written
informed consent
Exclusion Criteria:
- Subjects with a previous or suspected disease caused by N. meningitidis; or previous
immunization with a meningococcal vaccine or vaccine containing meningococcal
antigen(s); Any serious acute, chronic or progressive disease
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials